452 related articles for article (PubMed ID: 27164560)
1. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
[TBL] [Abstract][Full Text] [Related]
2. S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.
Wang Q; Zheng J; Zou JX; Xu J; Han F; Xiang S; Liu P; Chen HW; Wang J
Chem Biol Interact; 2020 Feb; 317():108965. PubMed ID: 32001260
[TBL] [Abstract][Full Text] [Related]
3. Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
Yang P; Guo L; Duan ZJ; Tepper CG; Xue L; Chen X; Kung HJ; Gao AC; Zou JX; Chen HW
Mol Cell Biol; 2012 Aug; 32(15):3121-31. PubMed ID: 22645312
[TBL] [Abstract][Full Text] [Related]
4. Nuclear TIGAR mediates an epigenetic and metabolic autoregulatory loop
Wang H; Wang Q; Cai G; Duan Z; Nugent Z; Huang J; Zheng J; Borowsky AD; Li JJ; Liu P; Kung HJ; Murphy L; Chen HW; Wang J
Acta Pharm Sin B; 2022 Apr; 12(4):1871-1884. PubMed ID: 35847493
[TBL] [Abstract][Full Text] [Related]
5. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
García-Carpizo V; Sarmentero J; Han B; Graña O; Ruiz-Llorente S; Pisano DG; Serrano M; Brooks HB; Campbell RM; Barrero MJ
Sci Rep; 2016 Sep; 6():32952. PubMed ID: 27604143
[TBL] [Abstract][Full Text] [Related]
6. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
[TBL] [Abstract][Full Text] [Related]
7. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Jan R; Huang M; Lewis-Wambi J
Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
[TBL] [Abstract][Full Text] [Related]
8. Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.
Wang JJ; Zou JX; Wang H; Duan ZJ; Wang HB; Chen P; Liu PQ; Xu JZ; Chen HW
Acta Pharmacol Sin; 2019 Aug; 40(8):1067-1075. PubMed ID: 30670815
[TBL] [Abstract][Full Text] [Related]
9. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
[TBL] [Abstract][Full Text] [Related]
10. NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-β/TGF-βRI/SMADs signaling.
Zhu L; Yu CL; Zheng Y
Biochem Biophys Res Commun; 2019 Nov; 519(3):489-496. PubMed ID: 31526565
[TBL] [Abstract][Full Text] [Related]
11. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
12. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.
Sun Y; Gu X; Zhang E; Park MA; Pereira AM; Wang S; Morrison T; Li C; Blenis J; Gerbaudo VH; Henske EP; Yu JJ
Cell Death Dis; 2014 May; 5(5):e1231. PubMed ID: 24832603
[TBL] [Abstract][Full Text] [Related]
13. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance.
Zou JX; Duan Z; Wang J; Sokolov A; Xu J; Chen CZ; Li JJ; Chen HW
Mol Cancer Res; 2014 Apr; 12(4):539-49. PubMed ID: 24391143
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
15. An epigenomic approach to therapy for tamoxifen-resistant breast cancer.
Feng Q; Zhang Z; Shea MJ; Creighton CJ; Coarfa C; Hilsenbeck SG; Lanz R; He B; Wang L; Fu X; Nardone A; Song Y; Bradner J; Mitsiades N; Mitsiades CS; Osborne CK; Schiff R; O'Malley BW
Cell Res; 2014 Jul; 24(7):809-19. PubMed ID: 24874954
[TBL] [Abstract][Full Text] [Related]
16. A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.
Sankaran SM; Wilkinson AW; Elias JE; Gozani O
J Biol Chem; 2016 Apr; 291(16):8465-74. PubMed ID: 26912663
[TBL] [Abstract][Full Text] [Related]
17. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
[TBL] [Abstract][Full Text] [Related]
18. An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.
Swaroop A; Oyer JA; Will CM; Huang X; Yu W; Troche C; Bulic M; Durham BH; Wen QJ; Crispino JD; MacKerell AD; Bennett RL; Kelleher NL; Licht JD
Oncogene; 2019 Jan; 38(5):671-686. PubMed ID: 30171259
[TBL] [Abstract][Full Text] [Related]
19. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
[TBL] [Abstract][Full Text] [Related]
20. A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing
Zhang P; Yang Y; Qian K; Li L; Zhang C; Fu X; Zhang X; Chen H; Liu Q; Cao S; Cui J
J Biol Chem; 2020 Oct; 295(41):14140-14152. PubMed ID: 32690611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
